NasdaqCM - Delayed Quote USD

Aditxt, Inc. (ADTX)

2.3500

-0.0600

(-2.49%)

At close: April 19 at 4:00 PM EDT

2.2900

-0.06

(-2.55%)

After hours: April 19 at 5:04 PM EDT

Loading Chart for ADTX

9/21 12:03 PM

DELL

Previous Close 2.4100
Open 2.4800
Bid 2.2600 x 100
Ask 2.3900 x 100
Day's Range 2.3000 - 2.4800
52 Week Range 2.2800 - 68.0800
Volume 14,557
Avg. Volume 371,752
Market Cap (intraday) 3.913M
Beta (5Y Monthly) 1.03
PE Ratio (TTM) --
EPS (TTM) -12.0000
Earnings Date --
Forward Dividend & Yield --
Ex-Dividend Date --
1y Target Est --

Aditxt, Inc., a biotech company, develops technologies focuses on improving the health of the immune system through immune mapping and reprogramming. The company develops AditxtScore that allows individuals to understand, manage, and monitor their immune profiles in order to be informed about attacks on or by their immune system; and Apoptotic DNA Immunotherapy, a nucleic acid-based technology that utilizes an approach that mimics the way the body naturally induces tolerance to its own tissues. It is also developing ADi products for organ transplantation, including skin grafting, autoimmune diseases, and allergies. Aditxt, Inc. has a license agreement with Loma Linda University and Leland Stanford Junior University. The company was formerly known as ADiTx Therapeutics, Inc. and changed its name to Aditxt, Inc. in July 2021. Aditxt, Inc. was incorporated in 2017 and is headquartered in Richmond, Virginia.

61

Full Time Employees

December 31

Fiscal Year Ends

Sector

Industry

Aditxt Signs a Definitive Agreement to Acquire Appili Therapeutics Inc., Developer of a Biodefense Vaccine Funded by the U.S. Department of Defense (DoD)

Evofem Reports $18.2 million of Phexxi Net Product Sales in 2023

Evofem Reports $18.2 million of Phexxi Net Product Sales in 2023

For Women Using GLP-1 Receptor Agonists who take Oral Birth Control Pills, Hormone-Free Phexxi Contraceptive Gel is a Logical Solution to Help Prevent Unintended Pregnancy

For Women Using GLP-1 Receptor Agonists who take Oral Birth Control Pills, Hormone-Free Phexxi Contraceptive Gel is a Logical Solution to Help Prevent Unintended Pregnancy

Evofem Biosciences Announces Strong Preliminary Results, Record Phexxi Net Sales for Fiscal 2023

Evofem Biosciences Announces Strong Preliminary Results, Record Phexxi Net Sales for Fiscal 2023

Aditxt, Inc. Acquires Proprietary Electroencephalography (EEG) Brain Monitoring Technologies and Devices, Including NeuroCap™ and NeuroEEG™ for Telehealth and Tele-neurology Applications

Aditxt, Inc.’s Subsidiary Pearsanta, Inc. Acquires MDNA Life Sciences Inc.’s Proprietary Mitomic™ Testing Platform Pioneering Early Disease and Cancer Detection in a Transaction Valued at Approximately $25 Million

Aditxt, Inc.’s Subsidiary Pearsanta, Inc. Acquires MDNA Life Sciences Inc.’s Proprietary Mitomic™ Testing Platform Pioneering Early Disease and Cancer Detection in a Transaction Valued at Approximately $25 Million

Aditxt Announces Closing of $6.0 Million Private Placement Priced At-The-Market under Nasdaq Rules

Aditxt, Inc. Regains Compliance with Nasdaq Stockholders’ Equity Requirement

Aditxt Announces $6 Million Private Placement Priced At-The-Market under Nasdaq Rules

Aditxt, Inc. Enters into Definitive Agreement to Acquire Evofem Biosciences, Inc., Creator of Phexxi®, the First and Only FDA-Approved Hormone-Free Contraceptive Gel, to Address Diverse Reproductive Health Needs of Women Globally

Aditxt, Inc. to Present at 8th Annual Dawson James Conference

Aditxt, Inc. to Present at 8th Annual Dawson James Conference

Aditxt, Inc. Announces Appointment of Ernie Lee as CEO of its Wholly-Owned Subsidiary, Pearsanta, to Lead Launch of Test2Treat.me Platform

Trailing total returns as of 4/19/2024, which may include dividends or other distributions. Benchmark is

.

YTD Return

ADTX

64.56%

S&P 500

4.14%

1-Year Return

ADTX

93.82%

S&P 500

19.55%

3-Year Return

ADTX

99.95%

S&P 500

18.68%

5-Year Return

ADTX

--

S&P 500

60.22%

Select to analyze similar companies using key performance metrics; select up to 4 stocks.

2.3500

-2.49%

Mkt Cap 3.913M

Industry Biotechnology

Evofem Biosciences, Inc.

0.0154

+9.22%

Mkt Cap 707,468

Industry Biotechnology

TransCode Therapeutics, Inc.

0.4850

-3.39%

Mkt Cap 2.817M

Industry Biotechnology

1.2300

-4.65%

Mkt Cap 3.326M

Industry Biotechnology

Hoth Therapeutics, Inc.

1.1955

+1.31%

Mkt Cap 5.845M

Industry Biotechnology

NeuroBo Pharmaceuticals, Inc.

3.3700

-0.88%

Mkt Cap 16.533M

Industry Biotechnology

ABVC BioPharma, Inc.

0.9901

-5.70%

Mkt Cap 10.456M

Industry Biotechnology

Phio Pharmaceuticals Corp.

0.6399

+0.77%

Mkt Cap 2.938M

Industry Biotechnology

Cardio Diagnostics Holdings, Inc.

0.8700

-20.18%

Mkt Cap 18.784M

Industry Biotechnology

Sonnet BioTherapeutics Holdings, Inc.

1.8200

+2.82%

Mkt Cap 5.587M

Industry Biotechnology

Biodexa Pharmaceuticals Plc

0.7520

-9.13%

Mkt Cap 3.196M

Industry Biotechnology

Valuation Measures

As of 4/19/2024

Market Cap

3.85M
Enterprise Value

21.97M
Trailing P/E

--
Forward P/E

--
PEG Ratio (5yr expected)

--
Price/Sales (ttm)

1.08
Price/Book (mrq)

0.24
Enterprise Value/Revenue

34.05
Enterprise Value/EBITDA

-0.86

Financial Highlights

Profitability and Income Statement

Profit Margin

0.00%
Return on Assets (ttm)

-117.53%
Return on Equity (ttm)

-698.60%
Revenue (ttm)

749.48k
Net Income Avi to Common (ttm)

-29.73M
Diluted EPS (ttm)

-12.0000

Balance Sheet and Cash Flow

Total Cash (mrq)

1.65M
Total Debt/Equity (mrq)

--
Levered Free Cash Flow (ttm)

-10.83M

Fair Value

Overvalued

% Return

2.3500 Current

Analyst Recommendations

Strong Buy
Buy
Hold
Underperform
Sell

Earnings

Consensus EPS

NRBO NeuroBo Pharmaceuticals, Inc.

3.3700

-0.88%

DBGI Digital Brands Group, Inc.

2.7250

-7.94%

PALI Palisade Bio, Inc.

4.7100

-7.10%

ENSC Ensysce Biosciences, Inc.

0.5710

-1.59%

ATXI Avenue Therapeutics, Inc.

0.1300

-2.26%

HOTH Hoth Therapeutics, Inc.

1.1955

+1.31%

SONN Sonnet BioTherapeutics Holdings, Inc.

1.8200

+2.82%

ADIL Adial Pharmaceuticals, Inc.

1.9300

-11.06%

NAOV NanoVibronix, Inc.

0.8000

+6.67%

FWBI First Wave BioPharma, Inc.

2.6000

-8.45%

AUVI Applied UV, Inc.

0.6525

-6.60%

PSTV Plus Therapeutics, Inc.

1.6300

-4.68%

ENVB Enveric Biosciences, Inc.

0.8806

-6.12%

SXTC China SXT Pharmaceuticals, Inc.

1.0200

+3.03%

KPRX Kiora Pharmaceuticals, Inc.

0.4903

-3.86%

ABVC ABVC BioPharma, Inc.

0.9901

-5.70%